What is new in pericytomatous, myoid, and myofibroblastic tumors?

Ivy John, Karen J Fritchie

Abstract readReview

In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Fibroma of tendon sheath is defined by a USP6 gene fusion-morphologic and molecular reappraisal of the entity.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ivy JohnDepartment of Anatomic Pathology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-4751-7678

Karen J FritchieDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Fritchie.Karen@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in molecular techniques in soft tissue pathology, including the widespread application of next-generation sequencing, have led to significant progress in our understanding of mesenchymal tumors. Recognition of the genetic signatures of these neoplasms not only clarifies the relationship of these entities but also provides a mechanism for more accurate diagnosis. More importantly, insight into the genetic underpinnings of these lesions may offer therapeutic targets for cases not amenable to surgical treatment. This review highlights the clinicopathologic features and novel molecular findings in pericytic, myoid, and myofibroblastic tumors.

Indexed as

FibromaGene RearrangementHumansMyofibromaNeoplasms, Connective and Soft TissuePericytesProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Receptor, Platelet-Derived Growth Factor betaZinc Finger Protein GLI1BRAF protein, humanGLI1 protein, humanKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Receptor, Platelet-Derived Growth Factor betaZinc Finger Protein GLI1Calcifying aponeurotic fibromaFibrous hamartoma of infancyGLI1LipofibromatosisPDGFRBPericytic neoplasmsSRF-RELA

Identifiers

PMID31705190

DOI10.1007/s00428-019-02700-y

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.